CVC's Petty: Deal Complexity Is the New Moat in Healthcare Private Equity

What's New

Cathrin Petty, Managing Partner, Co-Head of North American Private Equity and Global Head of Healthcare at CVC, made the case that operational execution on complex carveouts and founder partnerships is now the primary source of alpha in healthcare PE in a conversation on S&P Global's Private Markets 360. Petty built CVC's healthcare portfolio from zero to approximately €26 billion since 2016 and was appointed co-head of North American PE in 2025. Her argument is structural: in what she calls the most challenging environment in 30 years, firms that engineer bespoke solutions for sellers and avoid overleveraging will capture disproportionate returns.

Why It Matters

If Petty is right, healthcare PE is bifurcating between firms that can execute operational complexity and those that cannot. Geopolitical volatility, CMS uncertainty, and AI disruption are repricing deal flow toward situations where fewer bidders show up: corporate carveouts where the parent has never separated a business unit, and founder successions where the seller wants a partner rather than a price maximizer. CVC charges no arrangement, monitoring, or exit fees and concentrates compensation in deal-by-deal carry with a negative offset against underperformance. The firm's economics are the argument made tangible.

Big Picture Drivers

• Carveout execution speed: Petty contends most corporates pursuing divestitures are doing them for the first time. CVC's Theracos carveout from Malinckrodt moved from diligence to signing in four months and signing to closing in six, enabled by a dedicated ops team with a repeatable separation playbook. The parent needed to deleverage, and CVC's on-time delivery let them accelerate their own rebuild.

• Founder origination over auctions: CVC's two most recent US investments, GLI in gaming regulation and Bamboo in insurance, both came through direct founder relationships. The Recordati deal illustrates the model at scale: CVC spent 16 months building a business plan with an Italian family that had never acquired above a couple of hundred million, then transformed the company into a global rare disease platform. EBITDA grew from approximately €340 million to close to €1 billion.

• Technology as revenue recovery: The Teva women's health carveout was declining 10% annually at acquisition. CVC hired 550 people in 18 months, built systems from scratch, and trained a digital salesforce that launched products during COVID when competitors couldn't reach physicians. The topline was growing north of 16% at exit.

• Underleveraging as optionality: CVC runs lower leverage than many peers, which Petty argues provides capital structure flexibility for longer-term investments during uncertainty. The value creation thesis rests on topline acceleration and operational efficiency, not financial engineering.

By The Numbers

• €26 billion — CVC's healthcare portfolio, built from zero since 2016

• ~€1 billion — Recordati's current EBITDA, up from ~€340 million at entry

• 550 — Employees hired in 18 months to stand up the Teva women's health carveout

• 6 months — Signing to closing on the Theracos carveout from Malinckrodt

Key Trends to Watch

• Medical device re-entry: Petty says peers have shied away from devices, but CVC is investing across ophthalmology, heart-lung machines, and autoimmune management. Other large-cap GPs following CVC into device platforms would confirm the thesis that device complexity is mispriced.

• Corporate divestiture volume: The Malinckrodt deal was driven by deleveraging needs. If credit conditions remain restrictive through 2026 and 2027, carveout volume should rise, directly expanding the opportunity set for firms with separation playbooks.

• AI in clinical workflow: Petty identifies AI applied to diagnostics, patient identification, and labor allocation as the efficiency lever for demographic-driven demand. The test is whether portfolio companies report measurable throughput gains within 12 months.

Memorable Quotes

• "It is, I think, the most challenging environment that I've invested in the last 30 years." No caveats. The difficulty is the thesis.

• "How do you take a good company and make it a great company?" CVC's value creation philosophy in one sentence, and a clean separation from the leveraged buyout archetype.

• "In the event that those investments don't perform, that gets offset against our future investments until that is regained." The negative offset converts alignment rhetoric into economic consequence.

The Wrap

Petty is not calling a downturn. She is making an operational argument: uncertainty and disruption favor firms with execution infrastructure, global networks, and compensation structures that punish capital destruction. Her thesis succeeds if carveout and founder-originated deals keep offering better entry pricing and more controllable value creation than auctions. It fails if markets normalize fast enough for financial engineering to reassert dominance. For allocators, the question is whether their healthcare GP can do what CVC did with Theracos: diligence to fully separated standalone company in under a year. The firms that can demonstrate that today will set the terms for the next vintage. Those still building the capability will find themselves bidding against them.